Form 4: Prelude Therapeutics Officer Andrew Combs Acquires $69,250 in Common Stock

Andrew Combs, Chief Chemistry Officer of Prelude Therapeutics, reports purchasing 100,000 shares of common stock at $0.6925 per share.

Summary

• On March 25, 2025, Andrew Combs, the Chief Chemistry Officer of Prelude Therapeutics Inc., acquired 100,000 shares of common stock.
• The purchase price was $0.6925 per share.
• Following the transaction, Combs directly owns 480,123 shares of Prelude Therapeutics common stock.
• The reported total includes 2,500 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. An insider purchase is generally a good sign, but the amount is not significantly large relative to the officer's existing holdings.

Positives

• The purchase of shares by a company officer can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into a company's prospects. Purchases are generally viewed more favorably than sales.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Insider Trading, Prelude Therapeutics, PRLD, Andrew Combs, Chief Chemistry Officer, Common Stock, Acquisition